PrEP involves the daily use of a single tablet containing two antiretroviral medications to reduce the risk of infection in people who are HIV-negative and may be exposed to the virus.
PrEP has been shown to significantly reduce the risk of HIV infection in sexually active adolescents, adults and individuals who use drugs. The efficacy of PrEP depends on correct use (daily pill taking) of the intervention and can provide up to 99% protection. Unfortunately, PrEP is ineffective in preventing STIs, other than HIV. The best level of sexual protection is obtained from the use of condoms (for STI prevention) together with PrEP (for HIV prevention).
PrEP does not provide immediate protection from HIV as it takes time to build up sufficient levels in the body. It takes seven days of dosing to prevent the anal acquisition of HIV and up to 20 days to prevent a vaginal acquisition of the virus. It does not need to be taken lifelong but is designed to be used during risky life periods when there is potential for HIV exposure to occur.
Anova supports PrEP in the following ways: